Description
This product is a Human antibody that recognizes Human LILRB4. MAb h128-3 showed potent activity in blocking development of monocytic AML in various models including patient-derived xenograft (PDX) mice and syngeneic immunocompetent AML mice. MAb h128-3 enhanced the anti-AML efficacy of chemotherapy treatment by stimulating mobilization of leukemia cells.
Target
LILRB4
Target Alias Names
ILT3, LIR5, CD85K, ILT-3, LIR-5, leukocyte immunoglobulin-like receptor subfamily B member 4, CD85 antigen-like family member K, immunoglobulin-like transcript 3, leucocyte Ig-like receptor B4, leukocyte immunoglobulin-like receptor 5, leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 4, monocyte inhibitory receptor HM18
Isotype/Mimetic
Human IgG
Animal-Derived Biomaterials Used
None
Sequence Available
No
Original Discovery Method
Human-derived phage display
Original Discovery Information Provided On Datasheet
No
Antibody/Binder Origins
Animal-free discovery, In vitro recombinant expression

